Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT

Opko Health Inc. (NASDAQ:OPK) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts. In a report released on May 2, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Opko Health Inc. (NASDAQ:OPK) with a price target of $3.00. The rating update followed the company’s announcement of its fiscal Q1 2025 results, which included significant developments.

Is Opko Health Inc. (OPK) the Best Nasdaq Stock Under $5 to Buy?

A doctor in scrubs discussing a patient’s test results with a small group of concerned family members.

These included the sale of its BioReference laboratory testing businesses, which focused on oncology and oncology-related clinical testing services, for up to $225 million. The transaction includes a $192.5 million payout at closing and up to $32.5 million in a performance-based earnout.

Opko Health Inc. (NASDAQ:OPK) also announced a collaboration agreement with Entera Bio to advance oral GLP-1/glucagon tablet candidates into the clinic for the treatment of metabolic disorders and obesity. ModeX is also continuing advancements in its immuno-oncology and immunology portfolio, with a pipeline showing the progress of four potential clinical candidates.

Opko Health Inc. (NASDAQ:OPK) is a biopharmaceutical and diagnostics company that provides healthcare services. Its operations are divided into the Diagnostics and Pharmaceuticals segments.

While we acknowledge the potential of OPK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.